is not only the main cause of gastric cancer (GC), but is also closely associated with its metastasis. One of the major virulence factors in H. pylori is the cytotoxin-associated gene A (CagA). With the growing proportion of amoxicillin-resistant H. pylori strains, the present study aimed to explore the effects of CagAand penicillin-binding protein 1A (PBP1A) 
Introduction
Helicobacter pylori (H. pylori) is a gram-negative, microaerophilic bacterium that colonizes the gastric mucosa and infects ~50% of individuals worldwide. It has been categorized as a group I carcinogen for gastric cancer (GC) by the World Health Organization, and GC remains a major public health problem worldwide (1, 2) . A previous study revealed that the relative risk for the development of GC was 3.8-fold higher in patients with H. pylori infection compared to those without (3) . In addition, the association between H. pylori eradication and the reduced incidence of GC has been demonstrated in a meta-analysis study (4) . Nevertheless, with regards to the prognosis of GC, several studies have suggested that H. pylori infection is a favorable prognostic factor of GC in a Chinese prospective cohort (5, 6) . Conversely, other studies have indicated that H. pylori infection has no association with prognosis in Chinese patients (7, 8) . It was hypothesized that this discrepancy may be due to the fact that GC with different H. pylori genotypes exhibits different growth patterns and pathobiological behavior, indicating different mechanisms of cancer progression. Further knowledge regarding H. pylori-infected GC may help to identify novel therapeutic targets.
Treatment of H. pylori infection is often empiric and current guidelines recommend against the use of standard triple therapy (clarithromycin, amoxicillin and proton pump inhibitors) as first-line treatment (9) . However, the prevalence of amoxicillin-resistant H. pylori is very high in Africa (65.6%) and Asia (11.6%) (9,10). In H. pylori, resistance occurs through modifications in penicillin-binding proteins (PBPs), leading to a decreased affinity for the drug. These modifications include mutations and/or mosaics in PBP2X and PBP2B, as well as in PBP1A for the highly resistant isolates (11) . To date, the clinical significance of amoxicillin-resistant H. pylori (PBP1A mutation-positive H. pylori, H. pylori P+ ) in GC, and the role of H. pylori P+ in GC cell malignant behavior and its specific mechanism require further elucidation. Furthermore, the H. pylori genome shows genetic diversity among distinct isolates, and H. pylori pathogenicity is different in distinct isolates. Clinically isolated H. pylori strains are often subdivided into two types according to the cytotoxin-associated gene (Cag) pathogenicity island-encoded CagA protein (12) . Notably, CagA-positive H. pylori increases the risk for GC over the risk associated with H. pylori infection alone (13) . In addition, it has been reported that infections involving H. pylori strains that possess the virulence factor CagA have a worse clinical outcome than those involving CagA-negative strains (14) , and CagA is indispensable for H. pylori-induced tumorigenesis in GC (15) . Furthermore, CagA may promote epithelial-mesenchymal transition (EMT), which indicates a strong ability to induce invasion and metastasis of tumor cells, and to stimulate gastric carcinogenesis (16) . Therefore, in the present study, the role of CagA-and PBP1A mutation-positive H. pylori (H. pylori CagA+/P+ ) was investigated in patients with GC and in GC cells, in order to gain insights into the effects of H. pylori during the development of GC.
Factors intrinsic to the host may also contribute to the emergence of GC, and microRNAs (miRNAs/miRs) appear to serve an important role in the etiology of this disease (17) . miRNAs are noncoding RNAs that are involved in post-translational regulation of gene expression (18) . Unique miRNAs are associated with various histological subtypes, and the progression and prognosis of GC (19) . A previous study demonstrated that H. pylori may induce dysregulation of miRNAs, contributing to the etiology of H. pylori-mediated GC cases (17) . Therefore, the identification of signature miRNAs associated with H. pylori infection may provide novel insights into its carcinogenesis and the host mechanisms that are involved in bacterial elimination. However, whether miRNAs are involved in the effects of H. pylori CagA+/P+ on GC has received little attention.
The present study investigated the clinical significance of H. pylori CagA+/P+ in patients with GC, and explored the role of H. pylori CagA+/P+ in cell proliferation, invasion and EMT of GC cells in vitro, in order to uncover the potential mechanism underlying the effects of H. pylori CagA+/P+ on gastric carcinogenesis. Furthermore, the involvement of potential miRNAs in the pathogenesis of H. pylori CagA+/P+ -associated GC was observed.
Materials and methods
Patients, H. pylori strains and culture conditions. The present study was conducted between February 2014 and November 2017 at the Jiangsu Province Hospital of TCM (Nanjing, China). Gastric biopsy specimens were collected and maintained in selective tryptic soy broth as transport media for further processing, as recommended by Siu et al (20) . Only patients who were diagnosed with GC, and were negative or positive for H. pylori were recruited; patient characteristics are presented in Table I . A total of 184 pairs of GC tissues and adjacent non-tumor tissues were collected during surgery. None of the patients had received adjuvant chemotherapy, radiotherapy or H. pylori eradication treatment prior to surgery. The histological types, stages and types of treatment of the patients with GC were recorded. Samples obtained from each patient were collected for culture, and three clinical isolates were recovered from GC tissues, as previously described (21) , which were used in the present study. Identification of H. pylori was determined by colony morphology, Gram-staining, and biochemical profile reactions, such as oxidase, catalase and urease tests (22) . The molecular identification of CagA-positive and CagA-negative strains was conducted as previously described (23) . The amoxicillin-susceptible and amoxicillin-resistant H. pylori strains examined in this study were isolated from GC tissues. Amoxicillin resistance was identified by sub-culturing swabs of bacteria from isolation plates to horse blood agar plates with and without 0.5 mg/l amoxicillin (Merck KGaA, Darmstadt, Germany), as previously described (24) . A PBP1A mutation in the C-terminal region (encoded by amino acids 320-660) was validated using reverse transcription-polymerase chain reaction (RT-PCR) (22) ; the primers used were as follows: Forward, 5'-GCGACATCTGGATGAAAAT-3' and reverse, 5'-CCATTGTTCCAACATAATCA-3' (22) . All H. pylori strains were cultured on chocolate blood agar, and were incubated at 37˚C in a humidified incubator containing 10% CO 2 and 85% N 2 for 48 h.
Cell culture. The human gastric epithelial cell line (GES-1), and GC cell lines, MGC-803, BGC-823, SGC-7901 and MKN45, were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) and maintained in Roswell Park Memorial Institute (RPMI)-1640 medium (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA USA). 293T cells (Cell Bank of Chinese Academy of Sciences) were cultured in Dulbecco's modified Eagle's medium (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS. All cells were incubated at 37˚C in a humidified atmosphere containing 5% CO 2 .
H. pylori infection experiments. For cell infection, a single colony of a 3-day old culture was cultured in 5 ml broth (tryptone 10 g/l; yeast extract 5 g/l; NaCl 10 g/l in distilled water; pH 7.4) supplemented with 10% heat-inactivated FBS (Gibco; Thermo Fisher Scientific, Inc.). The bacterial cultures were incubated under microaerobic conditions generated by CampyGen sachets at 37˚C for 1-2 days with agitation at 150 rpm. When the 600 nm optical density of the bacterial culture in Brain Heart Infusion broth (HiMedia Laboratories, Mumbai, India) reached 1.0, the bacteria were harvested and incubated at 37˚C in RPMI medium for 30 min. SGC-7901 cells were microscopically enumerated using an improved Neubauer counting chamber. Monolayer SGC-7901 cells in a 6-well plate (10 5 /well) were incubated with H. pylori at a multiplicity of infection of 50:1 for 12 h at 37˚C and 10% CO 2 , as previously described (25) .
Cell transfection. miRNA mimic control (5'-UCACAACCUC CUAGAAAGAGUAGA-3'), miR-134 mimics (sense 5'-UGU GACUGGUUGACCAGAGGGG-3'; antisense 5'-CCUCUGG UCAACCAGUCACAUU-3'), inhibitor control (5'-UCACAA CCUCCUAGAAAGAGUAGA-3') and miR-134 inhibitors (5'-CCCCUCUGGUCAACCAGUCACA-3') were all purchased from Guangzhou Ribobio Co., Ltd. (Guangzhou, China). Forkhead box M1 (FoxM1)-specific small interfering RNA (siRNA; si-FOXM1; 5'-UGAAUCUGCGUUUUC ACUCUC-3') and negative control siRNA (5'-UGCAAAUAAGGGUAAUC AUGC-3') were synthesized by Shanghai GenePharma Co., Ltd. (Shanghai, China). Lipofectamine ® 2000 reagent (Invitrogen; Thermo Fisher Scientific, Inc.) was used to transfect the aforementioned oligonucleotides into SGC-7901 cells according to the manufacturer's protocol. Briefly, 5x10 5 cells were seeded into each well of 6-well plates 18-24 h prior to transfection. The transfection medium (2 ml) containing 1 µg/ml siRNAs or 100 nmol/l miRNA mimics/inhibitors together with 6 µl Lipofectamine ® 2000 was incubated at room temperature for 15 min and was then transferred to each well of the culture plates at 37˚C; the cells were harvested for analysis after 24 h. FoxM1 overexpression was achieved by transfecting SGC-7901 cells with the FoxM1 (NM_202002) plasmid (Shanghai GeneChem Co., Ltd., Shanghai, China). Attractene transfection reagent (Qiagen GmbH, Hilden, Germany) was used to transfect cells with the FoxM1 plasmid or an empty GV230 plasmid (Shanghai GeneChem Co., Ltd.), in accordance with the manufacturer's protocol.
miRNA microarray analysis. Five CagA-positive and PBP1a mutation-negative H. pylori (H. pylori CagA+/P-) and five H. pylori CagA+/P+ tumor tissue samples were selected for miRNA microarray analysis. Total RNA was isolated using TRIzol ® reagent (Invitrogen; Thermo Fisher Scientific, Inc.) and miRNeasy mini kit (Qiagen GmbH), according to the manufacturers' protocols. Total RNA was then labeled using the miRCURY™ Array Power labeling kit (Exiqon; Qiagen GmbH) and hybridization was performed using miRCURY™ LNA Array (Exiqon; Qiagen GmbH). Fluorescent images were collected using a laser scanner (GenePix 4000B; Molecular Devices, LLC, Sunnyvale, CA, USA) and were digitized using Array-Pro image analysis software 6.3 (Media Cybernetics, Inc., Rockville, MD, USA). The SpotData Pro 3.0 software (CapitalBio Corporation, Beijing, China) was used for data analysis. Hierarchical clustering was performed using Data Matching Software MeV v4.8.1 (26) .
RNA isolation and RT-quantitative (q)PCR analysis.
Total RNA was extracted from the treated cells using TRIzol ® reagent (Invitrogen; Thermo Fisher Scientific, Inc.). Total RNA was reverse transcribed using the cDNA Synthesis kit (Takara Biotechnology Co., Ltd., Dalian, China), according to the manufacturer's protocol, and quantification was performed using SYBR Green (Takara Biotechnology Co., Ltd.) on a LightCycler480 PCR system (Roche Diagnostics, Basel, Switzerland). Amplification of target gene cDNA was normalized to GAPDH expression. The expression levels of miR-134 were assessed using the Bulge-Loop™ miRNA qRT-PCR Primer Set and the miRNA qRT-PCR Control Primer Set (Guangzhou RiboBio Co., Ltd.), and U6 was used as an internal control. The primer sequences used are listed in Table II . The thermocycling conditions were as follows: 94˚C for 10 min, followed by 40 cycles at 94˚C for 10 sec, 60˚C for 45 sec and 72˚C for 60 sec, and a final extension step at 72˚C for 5 min. Each reaction was performed in triplicate. Relative quantification of gene expression levels was expressed as fold-change using the 2 -ΔΔCq method (27) . Each test was carried out in triplicate.
Western blot analysis. Radioimmunoprecipitation assay lysis buffer and Bicinchoninic Acid Protein Quantification kit (Beijing Solarbio Science & Technology Co., Ltd., Beijing, China) were employed to extract total protein from SGC-7901 cells and determine protein concentration, respectively.
Equal amounts of protein (30 µg) were separated by 10-12% SDS-PAGE, transferred to polyvinylidene fluoride membranes. After blocking with 5% non-fat milk at room temperature for 1 h, the membranes were incubated with E-cadherin (cat. no. 14472, 1:1,000), Vimentin (cat. no. 5741, 1:1,000), α-smooth muscle actin (α-SMA, cat. no. 48938, 1:1,000), FoxM1 (cat. no. 20459, 1:1,000) and GAPDH (cat. no. 2118, 1:1,000; Cell Signaling Technology, Inc., Danvers, MA, USA) antibodies overnight at 4˚C. The membranes were then incubated with goat anti-rabbit immunoglobulin (Ig) G H&L (horseradish peroxidase) (1:5,000; Abcam, Cambridge, MA, USA) for 1 h at room temperature. Membrane-bound immune complexes were visualized using the enhanced chemiluminescence detection reagent (Beyotime Institute of Biotechnology, Haimen, China).
Cell proliferation and invasion. Cell proliferation was measured using the Cell Counting Kit-8 (CCK-8; Dojindo Molecular Technologies, Inc., Kumamoto, Japan). At different time points, 10 µl CCK-8 solution was added to each well, and the plates were incubated at 37˚C for 2 h. Absorbance was measured at 570 nm using a Thermo Fisher Scientific Microplate Reader (Thermo Fisher Scientific, Inc.). The cell invasion assay was performed using Transwell chambers coated with Matrigel (EMD Millipore, Billerica, MA, USA). At 48 h post-transfection, 10 5 cells were added into the upper chambers alongside serum-free medium. In the lower chambers, 500 µl RPMI-1640 medium containing 10% FBS was added as a chemoattractant. After 24 h, the Matrigel and cells on the upper surface were removed by cotton swabs, and the cells that had migrated to the lower surface were fixed in 4% paraformaldehyde (Sigma-Aldrich; Merck KGaA) for 15 min at room temperature and stained with 0.1% crystal violet (Sigma-Aldrich; Merck KGaA) for 15 min at room temperature. Cells were visually counted in five randomly selected fields under a light microscope (Axiovert 200 inverted microscope; Zeiss AG, Oberkochen, Germany).
Luciferase assay and constructs. TargetScan (http://www. targetscan.org) and microRNA database (http://www.microrna. org) bioinformatics software were used to predict the downstream targets of miR-134. The FoxM1 promoter region was amplified from human genomic DNA (cat. no. Roche-11691112001; Sigma-Aldrich; Merck KGaA) by PCR (forward, 5'-GGTCCGAGTAAAACAAGAGCG-3'; reverse, 5'-AGTGAGAGAGTATAGGAAGG-3'). Mutated FoxM1, devoid of the miR-134 binding site, was generated using the QuikChange II XL Site-Directed Mutagenesis kit (cat. no. ST200521; Stratagene; Agilent Technologies, Inc., Santa Clara, CA, USA). Wild type and mutated FoxM1 were sub-cloned into the pGL3-basic luciferase vector (Promega Corporation, Madison, WI, USA). 293T cells, cultured in 24-well plates (5x10 5 ), were transfected with 2.4 µg/well wild type FoxM1-pGL3 plasmid or mutant FoxM1-pGL3 plasmid, and were co-transfected with 20 nmol/l miR-134 mimics or mimic control using 2 µl Lipofectamine ® 2000 transfection reagent (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. After 48 h of transfection, luciferase activity was measured using the Bright-Glo™ Luciferase Assay system (Promega Corporation) according to the manufacturer's protocol. Relative percentages of luminescence intensity were calculated by comparison with the mimic control-transfected cells.
Immunofluorescence analysis. After treatment, cells were fixed with 4% paraformaldehyde (Sigma-Aldrich; Merck KGaA) for 15 min at room temperature and blocked with 5% bovine serum albumin (Sigma-Aldrich; Merck KGaA) for 30 min at room temperature. The cells were then incubated with E-cadherin (1:400), α-SMA (1:500) or FoxM1 (1:500) primary antibodies overnight at 4˚C. After washing with PBS-0.1% Tween, cells were incubated with Alexa Fluor ® 488 goat anti-rabbit IgG (cat. no. A-11034) or Alexa Fluor ® 594 goat anti-rabbit IgG (cat. no. B40925; 1:500; Invitrogen; Thermo Fisher Scientific, Inc.) for 30 min at room temperature in the dark. DAPI (Sigma-Aldrich; Merck KGaA) was used to identify the nuclei. Images were captured under a Nikon Eclipse 800 epifluorescence microscope (Nikon Corporation, Tokyo, Japan) with the appropriate filters.
Statistical analysis. All experiments were performed at least three times and data are presented as the means ± standard error. Pearson's χ 2 test was used to investigate the associations between H. pylori status and categorical variables. Student's t-test was used to compare differences between two groups with continuous variables. One-way analysis of variance and least significant difference post hoc test was used to compare the differences between more than two groups. Pearson's correlation was used to analyze the relationship between miR-134 and FoxM1 expression. Statistical analyses were performed using SPSS 20.0 (IBM Corp., Armonk, NY, USA) and GraphPad Prism 6.0 (GraphPad Software Inc., La Jolla, CA, USA). P<0.05 was considered to indicate a statistically significant difference. Fig. 2A) . The present study further investigated the four most downregulated miRNAs, miR-134, miR-218, miR-159 and miR-488, and validated the microarray results using RT-qPCR. The expression levels of miR-134 were decreased in the H. pylori CagA-group compared with in the control group, and were further decreased in the H. pylori CagA+/P+ group (Fig. 2B) . Although miR-218 and miR488 were decreased in H. pylori-infected GC tissues, there was no significant difference between the different H. pylori strains (Fig. 2C and D) . In addition, miR-159 (Fig. 2E) . Based on these findings, the present study focused on miR-134, with the aim of identifying its regulatory role in H. pylori CagA+/P+ GC tissues.
Results

H. pyloriCagA+/P+ infection is
miR-134 inhibits HP-induced cell proliferation, invasion and reverses EMT.
In order to elucidate the relationship between miR-134 and H. pylori CagA+/P+ -induced malignant behavior of GC cells, proliferation, invasion and EMT of SGC-7901 cells were analyzed. As shown in Fig. 3A , miR-134 expression differed between GES-1 cells and the four GC cell lines. SGC-7901 cell exhibited the lowest miR-134 expression; therefore, it was then chosen for subsequent analyses. As presented in Fig. 3B , SGC-7901 cells exposed to H. pylori infection exhibited reduced miR-134 expression, and cells infected with H. pylori CagA+/P+ possessed the lowest expression levels of miR-134; these findings were consistent with the results from clinical samples. Therefore, SGC-7901 cells were transfected with miR-134 mimics to induce miR-134 overexpression (Fig. 3C) . Subsequently, CCK-8 and Transwell assays demonstrated that miR-134 overexpression significantly decreased H. pylori CagA+/P+ -induced cell proliferation and invasion compared with in the control group ( Fig. 3D and E) . As shown in Fig. 3F , miR-134 overexpression upregulated E-cadherin, and downregulated α-SMA expression. In addition, western blot analysis revealed consistent alterations in the aforementioned EMT markers in the H. pylori CagA+/P+ + miR-134 mimics groups compared with in the H. pylori CagA+/P+ group (Fig. 3G) . These findings indicated that miR-134 may act as a suppressor of proliferation, invasion and EMT in H. pylori CagA+/P+ -infected SGC-7901 cells.
FoxM1 is identified as a direct target of miR-134.
To determine the target gene of miR-134 in H. pylori CagA+/P+ -infected GC cells, candidate target genes were searched using bioinformatics analysis. The analysis revealed that FoxM1 possessed a putative miR-134-binding site (Fig. 4A) , which prompted further validation of this relationship. FoxM1 expression was significantly increased in H. pylori CagA+/P+ GC tissues compared with in H. pylori CagA+/P-GC tissues (Fig. 4B) . Correlation analysis revealed that FoxM1 expression was negatively correlated with miR-134 expression (Fig. 4C) . Subsequently, knockdown of miR-134 was achieved via transfection with miR-134 inhibitors; transfection efficiency was validated by RT-qPCR (Fig. 4D) . In response to miR-134 overexpression, the mRNA and protein expression levels of FoxM1 were significantly downregulated, whereas they were upregulated by miR-134 knockdown in SGC-7901 cells (Fig. 4E and F) . Dual luciferase reporter assay revealed that miR-134 mimics significantly suppressed FoxM1 wild type luciferase activity compared with in the mimics control group, but did not affect FoxM1 mutant type luciferase activity (Fig. 4G) . Furthermore, immunofluorescence assay demonstrated that miR-134 mimics decreased the expression of FoxM1 protein in H. pylori CagA+/P+ -infected cells (Fig. 4H) . These data suggested that FoxM1 was a direct target gene of miR-134 and was negatively regulated by miR-134.
Knockdown of FoxM1 impedes H. pylori-induced EMT.
Although elevated FoxM1 is identified as a prognostic factor for GC, whether it is involved in EMT in H. pylori CagA+/P+ -associated GC remains undefined. Therefore, si-FoxM1 was used to knockdown FoxM1 in H. pylori CagA+/P+ -infected SGC-7901 cells. The transfection efficiency of si-FoxM1 was determined using RT-qPCR and western blot analysis (Fig. 5A and B) . Subsequently, the role of FoxM1 in H. pylori CagA+/P+ -induced EMT was determined. Western blot analysis revealed that H. pylori-mediated EMT was significantly reversed by knockdown of FoxM1 (Fig. 5C) . Similarly, these findings were validated at the mRNA level, as evidenced by the alterations in EMT-associated genes (Fig. 5D-F ). These data revealed that H. pylori CagA+/P+ may trigger EMT of GC cells through regulation of FoxM1.
miR-134 exerts its tumor suppressor function through regulation of FoxM1.
Having demonstrated that FoxM1 is a target gene of miR-134, the present study further investigated whether it was involved in the miR-134-mediated role in H. pylori CagA+/P+ -infected GC cells. A FoxM1 plasmid was transfected into SGC-7901 cells, and the mRNA and protein expression levels of FoxM1 were significantly increased following transfection (Fig. 6A and B) . As illustrated in Fig. 6C and D, the inhibitory effects of miR-134 overexpression were reduced by co-transfection with FoxM1. Furthermore, western blotting (Fig. 6E) and RT-qPCR analysis (Fig. 6F-H) demonstrated that co-transfection with miR-134 mimics and FoxM1 markedly downregulated E-cadherin, and upregulated Vimentin and α-SMA compared with in the H. pylori CagA+/P+ + miR-134 mimics group. These data suggested that miR-134 may inhibit H. pylori CagA+/P+ -induced GC cell proliferation and invasion, and reverse EMT by regulating FoxM1 in SGC-7901 cells.
Discussion
The present study demonstrated that H. pylori CagA+/P+ was associated with poor clinicopathological characteristics in GC. In addition, H. pylori CagA+/P+ infection significantly promoted GC cell proliferation and invasion, and induced EMT of GC cells. The present results also demonstrated that H. pylori CagA+/P+ may promote GC cell malignant behavior through regulation of the miR-134/FoxM1 regulatory network. These data may help to further understand the role of H. pylori CagA+/P+ in gastric carcinogenesis. Although the causal association between H. pylori infection and GC incidence is well established, the exact associations between H. pylori and the progression of GC remain largely unknown (28) . The present study analyzed the association between H. pylori infection and the clinical characteristics of GC in GC patients without H. pylori infection, and in GC patients with H. pylori CagA-, H. pylori CagA+/P-and H. pylori CagA+/P+ infection. The results indicated that H. pylori CagA-infection was not significantly associated with patient characteristics. This finding was similar to the results of previous studies, which suggested that H. pylori infection has no association with prognosis in China, and the prognosis of H. pylori-negative GC is equally poor (29) . However, the present study demonstrated that patients infected with H. pyloriCagA+/Ppossessed a higher proportion of advanced characteristics than those with H. pylori CagA-. This result was also supported by the findings that patients with H. pylori CagA+ GC had a worse clinical outcome than those involving H. pylori . Furthermore, distinct characteristics between H. pylori CagA+/Pand H. pylori CagA+/P+ GC were observed. Therefore, the present study focused on the role of PBP1A-mutated H. pylori strains. In in vitro-selected amoxicillin-resistant H. pylori strains, the resistance has been suggested to result from alterations in PBP1A (30, 31) . A single serine-to-arginine substitution in PBP1A induces high-level amoxicillin resistance in H. pylori (32) , which may explain the increase in naturally occurring H. pylori strains with a high level of amoxicillin resistance in recent years. Currently, amoxicillin remains one of the first-line antibiotics used for prophylaxis and treatment of H. pylori; however, the clinical significance of H. pylori CagA+/P+ in GC remains largely unknown. The present study revealed that H. pylori CagA+/P+ infection was significantly associated with various clinicopathological parameters, including invasion depth, lymphatic metastasis and distant metastasis. However, due to problems with follow-up, the 5 year overall or disease-free survival rates among the different H. pylori strain-infected cohorts were not analyzed. The present study hypothesized that H. pylori CagA+/P+ infection may be associated with a poorer outcome for patients with GC as compared to those with H. pylori CagA+/P-infection.
The present study further investigated the mechanisms underlying the clinical significance of H. pylori CagA+/P+ infection. EMT is a well-characterized embryological process that serves a critical role in tumor metastasis. EMT is characterized by the loss of epithelial markers (e.g., E-cadherin) and the acquisition of mesenchymal markers (e.g., Vimentin and α-SMA) (33) . The present results revealed that H. pylori CagA+/P+ induced a significant increase in cell proliferation and invasion, a decrease in E-cadherin expression, and an increase in Vimentin and α-SMA expression. Furthermore, since emerging evidence has suggested that miRNAs serve an important role in the control of H. pylori infection-associated responses in GC (34) Aberrant levels of miR-134 have been detected in various malignancies, and may regulate tumor development, differentiation, proliferation, invasion and metastasis (35, 36) . Overexpression of miR-134 inhibits migration, invasion and EMT of lung cancer cells by targeting integrin β1 mRNA (37) . Similarly, Zha et al revealed that miR-134 specifically targets integrin β1 to suppress the invasion and metastasis of hepatocellular carcinoma cells in vitro and in vivo (38) . Additionally, forced expression of miR-134 inhibits the migration and invasion of renal cell carcinoma cells by blocking EMT (39) . These findings indicated the miR-134 may serve as a tumor suppressor in human cancer (40) ; however, the pathogenetic roles of miR-134 were obscure in GC, particularly in GC associated with H. pylori infection. To the best of our knowledge, the current study was the first to reveal that forced overexpression of miR-134 could significantly reverse H. pylori CagA+/P+ infection-induced cell proliferation, invasion and EMT. Notably, the molecular and modulated mechanisms of miRNA are complex and variable (41) , and a recent study revealed that miR-134 has diverse target genes in cancer (40) . Using bioinformatics analysis and molecular experiments, the present study demonstrated that the downregulation of miR-134 in H. pylori CagA+/P+ -infected GC tissues was associated with upregulated FoxM1 mRNA and protein expression. In agreement with the sequence alignment, the luciferase reporter assays confirmed the direct targeting of the FoxM1 3'-untranslated region by miR-134, and suggested that a strong affinity may exist between miR-134 and FoxM1 mRNA in patients with GC and H. pylori CagA+/P+ infection. FoxM1 shares homology with the winged helix DNA-binding domain and is predominantly expressed in fetal tissue. It is maintained ubiquitously in all proliferating adult tissues and some cancer cell lines, whereas its expression is absent from differentiated cells (42) . The role of FoxM1 in the progression of GC has previously been investigated. Promotion of gastric tumorigenesis by FoxM1 is directly and significantly correlated with transactivation of vascular endothelial growth factor expression and elevation of angiogenesis (43) . Increased FOXM1 expression is also associated with invasive and metastatic processes in GC, and is inversely associated with patient prognosis (44) . Mechanistically, FOXM1 promotes GC cell migration and invasion through inducing the expression of Cath-D (45) . Furthermore, a negative correlation has been identified between FoxM1 and E-cadherin expression in GC tissue (46) . E-cadherin is associated with epithelial phenotypes, which serve a critical role in the process of EMT (47) . In accordance with the previous study, the present results indicated that knockdown of FoxM1 significantly abolished H. pylori-induced EMT of SGC-7901 cells. The functional studies revealed that the effects of miR-134 on cell proliferation, invasion and EMT were reversed by FoxM1 overexpression. Although a previous study revealed that FoxM1 is overexpressed in H. pylori CagA+ -induced gastric carcinogenesis and is regulated by miR-370 (48), the present study is the first, to the best of our knowledge, to suggest that FoxM1 was involved in H. pylori CagA+/P+ -mediated GC cell EMT and was negatively controlled by miR-134, delineating the mechanisms governing FoxM1 regulation in GC.
The present study has numerous limitations. The number of clinical samples used in this study was relatively small and further studies are required to validate the role of H. pylori CagA+/P+ infection in patients with GC. Additionally, H. pylori infections in many patients are asymptomatic and only a few people develop clinical disease (49) . However, focusing on the pathways implicated in H. pylori-induced tumorigenesis may lead to novel therapeutic strategies for GC prevention. In addition, with the growing proportion of amoxicillin-resistant H. pylori, a kit for detection of PBP1A mutations would be beneficial in clinical practice.
In conclusion, the present study revealed that H. pylori CagA+/P+ was associated with poor clinicopathological characteristics in patients with GC. In addition, H. pylori CagA+/P+ induced significant cell proliferation, invasion and EMT of GC cells. Mechanistically, H. pylori CagA+/P+ promoted EMT of GC cells through suppressing miR-134, which targeted FoxM1 in GC.
